2012 Q3 Form 10-Q Financial Statement
#000110465912074731 Filed on November 06, 2012
Income Statement
| Concept | 2012 Q3 | 2011 Q3 |
|---|---|---|
| Revenue | $96.41M | $12.22M |
| YoY Change | 689.11% | 34.87% |
| Cost Of Revenue | $0.00 | |
| YoY Change | ||
| Gross Profit | $96.40M | |
| YoY Change | ||
| Gross Profit Margin | 99.99% | |
| Selling, General & Admin | $22.85M | $10.90M |
| YoY Change | 109.6% | 67.69% |
| % of Gross Profit | 23.7% | |
| Research & Development | $23.45M | $22.91M |
| YoY Change | 2.39% | 22.21% |
| % of Gross Profit | 24.33% | |
| Depreciation & Amortization | $3.000M | $2.300M |
| YoY Change | 30.43% | 53.33% |
| % of Gross Profit | 3.11% | |
| Operating Expenses | $48.81M | $33.83M |
| YoY Change | 44.25% | 34.13% |
| Operating Profit | $47.61M | -$21.62M |
| YoY Change | -320.24% | 33.72% |
| Interest Expense | $14.00K | $16.00K |
| YoY Change | -12.5% | -80.25% |
| % of Operating Profit | 0.03% | |
| Other Income/Expense, Net | $27.00K | $986.0K |
| YoY Change | -97.26% | 821.5% |
| Pretax Income | $47.64M | -$20.63M |
| YoY Change | -330.9% | 28.47% |
| Income Tax | $0.00 | $3.000K |
| % Of Pretax Income | 0.0% | |
| Net Earnings | $47.64M | -$20.60M |
| YoY Change | -331.24% | 205.32% |
| Net Earnings / Revenue | 49.41% | -168.6% |
| Basic Earnings Per Share | $0.44 | -$0.21 |
| Diluted Earnings Per Share | $0.42 | -$0.21 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 107.3M shares | 100.2M shares |
| Diluted Shares Outstanding | 114.3M shares | 100.2M shares |
Balance Sheet
| Concept | 2012 Q3 | 2011 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $193.3M | $175.1M |
| YoY Change | 10.39% | -30.18% |
| Cash & Equivalents | $125.9M | $68.82M |
| Short-Term Investments | $67.50M | $106.3M |
| Other Short-Term Assets | $7.900M | $2.900M |
| YoY Change | 172.41% | -60.81% |
| Inventory | $965.0K | |
| Prepaid Expenses | ||
| Receivables | $169.0K | $700.0K |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $202.3M | $178.8M |
| YoY Change | 13.17% | -32.09% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $36.47M | $32.90M |
| YoY Change | 10.85% | -1.2% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $54.00K | $7.800M |
| YoY Change | -99.31% | -2.5% |
| Total Long-Term Assets | $44.17M | $40.70M |
| YoY Change | 8.53% | -1.21% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $202.3M | $178.8M |
| Total Long-Term Assets | $44.17M | $40.70M |
| Total Assets | $246.5M | $219.5M |
| YoY Change | 12.31% | -27.91% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $2.652M | $2.400M |
| YoY Change | 10.5% | -59.32% |
| Accrued Expenses | $16.69M | $16.90M |
| YoY Change | -1.25% | 42.02% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $300.0K | $200.0K |
| YoY Change | 50.0% | 0.0% |
| Total Short-Term Liabilities | $35.58M | $70.85M |
| YoY Change | -49.78% | 26.97% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $400.0K | $500.0K |
| YoY Change | -20.0% | 25.0% |
| Other Long-Term Liabilities | $28.50M | $35.20M |
| YoY Change | -19.03% | -56.11% |
| Total Long-Term Liabilities | $28.90M | $35.70M |
| YoY Change | -19.05% | -55.71% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $35.58M | $70.85M |
| Total Long-Term Liabilities | $28.90M | $35.70M |
| Total Liabilities | $64.40M | $106.6M |
| YoY Change | -39.59% | -21.9% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$461.2M | |
| YoY Change | ||
| Common Stock | $643.2M | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $182.1M | $112.9M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $246.5M | $219.5M |
| YoY Change | 12.32% | -27.92% |
Cashflow Statement
| Concept | 2012 Q3 | 2011 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $47.64M | -$20.60M |
| YoY Change | -331.24% | 205.32% |
| Depreciation, Depletion And Amortization | $3.000M | $2.300M |
| YoY Change | 30.43% | 53.33% |
| Cash From Operating Activities | $39.00M | -$25.40M |
| YoY Change | -253.54% | 11.4% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$3.600M | -$500.0K |
| YoY Change | 620.0% | -92.31% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $2.800M | $46.10M |
| YoY Change | -93.93% | -13.35% |
| Cash From Investing Activities | -$600.0K | $45.50M |
| YoY Change | -101.32% | -2.57% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 500.0K | 600.0K |
| YoY Change | -16.67% | -200.0% |
| NET CHANGE | ||
| Cash From Operating Activities | 39.00M | -25.40M |
| Cash From Investing Activities | -600.0K | 45.50M |
| Cash From Financing Activities | 500.0K | 600.0K |
| Net Change In Cash | 38.90M | 20.70M |
| YoY Change | 87.92% | -11.16% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $39.00M | -$25.40M |
| Capital Expenditures | -$3.600M | -$500.0K |
| Free Cash Flow | $42.60M | -$24.90M |
| YoY Change | -271.08% | 52.76% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2012Q3 | irwd |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
6154000 | USD |
| CY2012Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
16689000 | USD |
| CY2012Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9044014 | shares |
| CY2011Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
16043005 | shares |
| dei |
Entity Registrant Name
EntityRegistrantName
|
IRONWOOD PHARMACEUTICALS INC | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001446847 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2012-09-30 | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2012 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1. Nature of Business</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Ironwood Pharmaceuticals, Inc. (the “Company”) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking.  The Company’s lead product, linaclotide, will be marketed in the United States (“U.S.”) under the trademarked name of LINZESS. On August 30, 2012, the United States Food and Drug Administration (“FDA”) approved LINZESS as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”). LINZESS is the first FDA-approved guanylate cyclase type-C (“GC-C”) agonist and it was shown in clinical trials to help relieve abdominal pain and constipation associated with IBS-C and improve constipation symptoms associated with CIC. LINZESS is being commercialized in the U.S. by the Company and its collaboration partner, Forest Laboratories, Inc. (“Forest”) and will become commercially available for the first time in December 2012.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In September 2011, the Company’s European partner, Almirall, S.A. (“Almirall”) submitted a Market Authorization Application (“MAA”) to the European Medicines Agency (“EMA”) for linaclotide for the treatment of patients with IBS-C, and Almirall continues to work with the EMA in its review. On September 21, 2012, the EMA’s European Committee for Medicinal Products for Human Use, which provides non-binding recommendations for consideration by the EMA, issued a positive opinion recommending the marketing approval for linaclotide for the treatment of moderate to severe IBS-C in adults.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Astellas Pharma Inc. (“Astellas”), the Company’s partner for Japan and certain other Asian countries, continues to develop linaclotide for the treatment of patients with IBS-C in its territory.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company continues to assess alternatives to bring linaclotide to IBS-C and CIC sufferers in the parts of the world outside of its partnered territories. In May 2012, the Company submitted a Clinical Trial Application (“CTA”) to China’s State Food and Drug Administration for a Phase 3 trial of linaclotide in patients with IBS-C. The CTA has been accepted for review. In October 2012, the Company also entered into a collaboration agreement with AstraZeneca AB (“AstraZeneca”) to co-develop and co-commercialize linaclotide in China (Note 13).</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company continues to assess opportunities to expand the utility of linaclotide as well as the patient population who could benefit from linaclotide to ensure that it is maximizing the drug’s potential value. As part of its long-term strategy, the Company and Forest initiated a Phase 3b clinical trial to further characterize the effect of linaclotide on abdominal symptoms in patients with CIC. In addition, the Company continues to explore the potential for linaclotide in other patient populations as well as in other gastrointestinal indications.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company also has a pipeline focused on early development candidates and discovery research in multiple therapeutic areas, including gastrointestinal disease, central nervous system (“CNS”) disorders, respiratory disease and cardiovascular disease.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. The Company currently operates in one reportable business segment—human therapeutics.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company has generated an accumulated deficit as of September 30, 2012 of approximately $461.2 million since inception. In February 2010, the Company completed its initial public offering of Class A common stock and raised a total of approximately $203.2 million in net proceeds. Additionally, in February 2012, the Company sold 6,037,500 shares of its Class A common stock through a follow-on public offering and raised a total of approximately $85.2 million in net proceeds (Note 10).</font></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table> | ||
| CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
87282000 | USD |
| CY2011Q4 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
76734000 | USD |
| CY2011Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
74000 | USD |
| CY2011Q4 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
578000 | USD |
| CY2011Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2899000 | USD |
| CY2011Q4 | us-gaap |
Assets Current
AssetsCurrent
|
167567000 | USD |
| CY2011Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
7647000 | USD |
| CY2011Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
33625000 | USD |
| CY2011Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
138000 | USD |
| CY2011Q4 | us-gaap |
Assets
Assets
|
208977000 | USD |
| CY2011Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
6436000 | USD |
| CY2011Q4 | irwd |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
7010000 | USD |
| CY2011Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
11122000 | USD |
| CY2011Q4 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
233000 | USD |
| CY2011Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
4042000 | USD |
| CY2011Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
36291000 | USD |
| CY2011Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.21 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
61869000 | USD | |
| CY2011Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
986000 | USD |
| CY2011Q4 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
422000 | USD |
| CY2011Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
12435000 | USD |
| CY2011Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
21130000 | USD |
| CY2011Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2012Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2012Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2011Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2011Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
542141000 | USD |
| CY2011Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-432392000 | USD |
| CY2011Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
6000 | USD |
| CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
109856000 | USD |
| CY2011Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
208977000 | USD |
| CY2012Q3 | us-gaap |
Assets Current
AssetsCurrent
|
202347000 | USD |
| CY2012Q3 | us-gaap |
Assets
Assets
|
246518000 | USD |
| CY2012Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
35577000 | USD |
| CY2012Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
246518000 | USD |
| CY2012Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2011Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2012Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
75000000 | shares |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
75000000 | shares |
| CY2012Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2012Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2011Q3 | us-gaap |
Revenues
Revenues
|
12218000 | USD |
| us-gaap |
Revenues
Revenues
|
33717000 | USD | |
| CY2011Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
22905000 | USD |
| CY2011Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
10929000 | USD |
| CY2011Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
33834000 | USD |
| CY2012Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
47635000 | USD |
| CY2011Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-21616000 | USD |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
30958000 | USD | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
92827000 | USD | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-59110000 | USD | |
| CY2011Q3 | us-gaap |
Interest Expense
InterestExpense
|
16000 | USD |
| CY2011Q3 | us-gaap |
Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
|
105000 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
49000 | USD | |
| us-gaap |
Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
|
384000 | USD | |
| us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
900000 | USD | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1235000 | USD | |
| CY2011Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-20633000 | USD |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-57878000 | USD | |
| us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
3000 | USD | |
| CY2012Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
125867000 | USD |
| CY2011Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
100174100 | shares |
| CY2011Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
100174100 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
99699545 | shares | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
99699545 | shares | |
| CY2012Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
48805000 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
152127000 | USD | |
| CY2012Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
47635000 | USD |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-28769000 | USD | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
7323000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
8511000 | USD | |
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-1851000 | USD | |
| us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
-2833000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-2424000 | USD | |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-82000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1064000 | USD | |
| irwd |
Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
|
-511000 | USD | |
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-32873000 | USD | |
| irwd |
Increase Decrease In Deferred Rent Payables
IncreaseDecreaseInDeferredRentPayables
|
-396000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-67536000 | USD | |
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
81524000 | USD | |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
177075000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
6033000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
89522000 | USD | |
| us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
206000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
2513000 | USD | |
| us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
24499000 | USD | |
| us-gaap |
Interest Paid
InterestPaid
|
47000 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
325000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-47174000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-2147000 | USD | |
| us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
38585000 | USD | |
| CY2010Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
44321000 | USD |
| CY2011Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
68820000 | USD |
| CY2011Q3 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
897000 | USD |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Use of Estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The preparation of consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company’s management evaluates its estimates, including those related to revenue recognition, available-for-sale securities, inventory valuation and related reserves, impairment of long-lived assets, income taxes including the valuation allowance for deferred tax assets, research and development expense, contingencies and share-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p></td></tr></table> | ||
| CY2011Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
77200000 | USD |
| CY2012Q3 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
33000000 | USD |
| CY2011Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-20630000 | USD |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-57875000 | USD | |
| CY2011Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
3000 | USD |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
3000 | USD | |
| us-gaap |
Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
|
16600000 | USD | |
| CY2012Q3 | irwd |
Long Term Purchase Commitment Amount Remainder Of Fiscal Year
LongTermPurchaseCommitmentAmountRemainderOfFiscalYear
|
18100000 | USD |
| CY2012Q3 | irwd |
Long Term Purchase Commitment Amount First Full Fiscal Year
LongTermPurchaseCommitmentAmountFirstFullFiscalYear
|
7300000 | USD |
| CY2012Q3 | irwd |
Long Term Purchase Commitment Amount Second Full Fiscal Year
LongTermPurchaseCommitmentAmountSecondFullFiscalYear
|
9600000 | USD |
| CY2012Q3 | irwd |
Long Term Purchase Commitment Amount Third Full Fiscal Year
LongTermPurchaseCommitmentAmountThirdFullFiscalYear
|
9700000 | USD |
| CY2012Q3 | irwd |
Long Term Purchase Commitment Amount Fourth Full Fiscal Year
LongTermPurchaseCommitmentAmountFourthFullFiscalYear
|
9700000 | USD |
| CY2012Q3 | irwd |
Long Term Purchase Commitment Amount Fifth Full Fiscal Year
LongTermPurchaseCommitmentAmountFifthFullFiscalYear
|
5900000 | USD |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
93000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
87906000 | USD | |
| irwd |
Proceeds From Stock Options Exercised And Essp And Issuance Of Restricted Stock
ProceedsFromStockOptionsExercisedAndESSPAndIssuanceOfRestrictedStock
|
2719000 | USD | |
| CY2012Q3 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
280000 | USD |
| CY2012Q3 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
4531000 | USD |
| CY2012Q3 | irwd |
Undistributed Earnings Exchange Ratio Basis
UndistributedEarningsExchangeRatioBasis
|
1 | |
| us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | segment | |
| irwd |
Available For Sale Securities Debt Maturity Period Range High
AvailableForSaleSecuritiesDebtMaturityPeriodRangeHigh
|
P1Y | ||
| CY2012Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-461161000 | USD |
| CY2012Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5135000 | USD |
| CY2011Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2862000 | USD |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
12912000 | USD | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
8511000 | USD | |
| CY2012Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
47651000 | USD |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-28768000 | USD | |
| CY2011Q4 | us-gaap |
Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions
|
12 | item |
| CY2011Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.21 | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-28769000 | USD | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.58 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.58 | ||
| CY2012Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
182108000 | USD |
| CY2012Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
47608000 | USD |
| CY2012Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
27000 | USD |
| CY2011Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
76728000 | USD |
| CY2011Q4 | us-gaap |
Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
|
16000 | USD |
| CY2011Q4 | us-gaap |
Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
|
10000 | USD |
| CY2011Q4 | us-gaap |
Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
|
76734000 | USD |
| CY2012Q3 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
67449000 | USD |
| CY2012Q3 | us-gaap |
Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
|
12000 | USD |
| CY2012Q3 | us-gaap |
Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
|
5000 | USD |
| CY2012Q3 | us-gaap |
Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
|
67456000 | USD |
| CY2012Q3 | us-gaap |
Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions
|
10 | item |
| CY2012Q3 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
|
16800000 | USD |
| CY2011Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
|
35500000 | USD |
| CY2012Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
107266823 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
106036522 | shares | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
18922366 | shares | |
| CY2012Q3 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
6996544 | shares |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
16043005 | shares | |
| CY2012Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
114337327 | shares |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
106036522 | shares | |
| CY2012Q3 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
2141000 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-28862000 | USD | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-8000 | USD | |
| us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
4000 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
85228000 | USD | |
| CY2012Q3 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
67456000 | USD |
| CY2012Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
169000 | USD |
| CY2012Q3 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
13000 | USD |
| CY2012Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
7877000 | USD |
| CY2012Q3 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
7647000 | USD |
| CY2012Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
36470000 | USD |
| CY2012Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
54000 | USD |
| CY2012Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2652000 | USD |
| CY2012Q3 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
3130000 | USD |
| CY2012Q3 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
361000 | USD |
| CY2012Q3 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
9690000 | USD |
| CY2012Q3 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
18782000 | USD |
| CY2012Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
643154000 | USD |
| CY2012Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.44 | |
| CY2012Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
7000 | USD |
| CY2012Q3 | us-gaap |
Revenues
Revenues
|
96413000 | USD |
| CY2012Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
23453000 | USD |
| CY2012Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
25352000 | USD |
| CY2012Q3 | us-gaap |
Interest Expense
InterestExpense
|
14000 | USD |
| CY2012Q3 | us-gaap |
Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
|
41000 | USD |
| CY2012Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.42 | |
| CY2011Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-20680000 | USD |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-57873000 | USD | |
| us-gaap |
Revenues
Revenues
|
123265000 | USD | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
66926000 | USD | |
| us-gaap |
Interest Expense
InterestExpense
|
41000 | USD | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
85201000 | USD | |
| us-gaap |
Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
|
134000 | USD | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.27 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.27 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
8522000 | USD | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-20000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
12912000 | USD | |
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-840000 | USD | |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-84000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
3311000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
4978000 | USD | |
| irwd |
Increase Decrease In Accrued Research And Development Expense
IncreaseDecreaseInAccruedResearchAndDevelopmentExpense
|
-856000 | USD | |
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-35509000 | USD | |
| irwd |
Increase Decrease In Deferred Rent Payables
IncreaseDecreaseInDeferredRentPayables
|
-2256000 | USD | |
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
60896000 | USD | |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
69335000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
10595000 | USD | |
| us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
9000 | USD | |
| irwd |
Proceeds From Stock Options Exercised And Essp And Issuance Of Restricted Stock
ProceedsFromStockOptionsExercisedAndESSPAndIssuanceOfRestrictedStock
|
2881000 | USD | |
| us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
203000 | USD | |
| us-gaap |
Interest Paid
InterestPaid
|
16000 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
247000 | USD | |
| CY2012Q3 | us-gaap |
Inventory Net
InventoryNet
|
965000 | USD |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
965000 | USD |
